CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

被引：157

作者：

Herukka, SK

Hallikainen, M

Soininen, H

Pirttilä, T ^{[1
]}

机构：

[1] Kuopio Univ Hosp, Dept Neurol, Kuopio 70211, Finland

[2] Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland

来源：

NEUROLOGY | 2005年 / 64卷 / 07期

关键词：

D O I：

10.1212/01.WNL.0000156914.16988.56

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Baseline CSF amyloid beta-peptide-42 (A beta 42), tau, and phosphorylated tau (P-tau) levels from 46 control subjects and 78 patients with mild cognitive impairment (MCI) were measured. Twenty-three patients with MCI developed dementia during the study. Abnormal biomarkers were found early in the course of Alzheimer disease (AD). The most predictive assay for AD among the patients with MCI was the combination of A beta 42 and P-tau.

引用

收藏

页码：1294 / 1297

页数：4

相关论文

共 10 条

[1] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice [J].

Andreasen, N ;

Minthon, L ;

Davidsson, P ;

Vanmechelen, E ;

Vanderstichele, H ;

Winblad, B ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 2001, 58 (03) :373-379

[2] CSF markers for incipient Alzheimer's disease [J].

Blennow, K ;

Hampel, H .

LANCET NEUROLOGY, 2003, 2 (10) :605-613

[3] High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype [J].

Galasko, D ;

Chang, L ;

Motter, R ;

Clark, CM ;

Kaye, J ;

Knopman, D ;

Thomas, R ;

Kholodenko, D ;

Schenk, D ;

Lieberburg, I ;

Miller, B ;

Green, R ;

Basherad, R ;

Kertiles, L ;

Boss, MA ;

Seubert, P .

ARCHIVES OF NEUROLOGY, 1998, 55 (07) :937-945

[4] Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment [J].

Hampel, H ;

Teipel, SJ ;

Fuchsberger, T ;

Andreasen, N ;

Wiltfang, J ;

Otto, M ;

Shen, Y ;

Dodel, R ;

Du, Y ;

Farlow, M ;

Möller, HJ ;

Blennow, K ;

Buerger, K .

MOLECULAR PSYCHIATRY, 2004, 9 (07) :705-710

[5] Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF [J].

Hulstaert, F ;

Blennow, K ;

Ivanoiu, A ;

Schoonderwaldt, HC ;

Riemenschneider, M ;

De Deyn, PP ;

Bancher, C ;

Cras, P ;

Wiltfang, J ;

Mehta, PD ;

Iqbal, K ;

Pottel, H ;

Vanmechelen, E ;

Vanderstichele, H .

NEUROLOGY, 1999, 52 (08) :1555-1562

[6] Mild cognitive impairment represents early-stage Alzheimer disease [J].

Morris, JC ;

Storandt, M ;

Miller, JP ;

McKeel, DW ;

Price, JL ;

Rubin, EH ;

Berg, L .

ARCHIVES OF NEUROLOGY, 2001, 58 (03) :397-405

[7] Current concepts in mild cognitive impairment [J].

Petersen, RC ;

Doody, R ;

Kurz, A ;

Mohs, RC ;

Morris, JC ;

Rabins, PV ;

Ritchie, K ;

Rossor, M ;

Thal, L ;

Winblad, B .

ARCHIVES OF NEUROLOGY, 2001, 58 (12) :1985-1992

[8] Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment [J].

Riemenschneider, M ;

Lautenschlager, N ;

Wagenpfeil, S ;

Diehl, J ;

Drzezga, A ;

Kurz, A .

ARCHIVES OF NEUROLOGY, 2002, 59 (11) :1729-1734

[9] Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease [J].

Schönknecht, P ;

Pantel, J ;

Hunt, A ;

Volkmann, M ;

Buerger, K ;

Hampel, H ;

Schröder, J .

NEUROSCIENCE LETTERS, 2003, 339 (02) :172-174

[10]

Sjögren M, 2001, CLIN CHEM, V47, P1776